(Q47824958)

5 February 2018

title

Generation of CTL responses against pancreatic cancer in vitro using dendritic cells co-transfected with MUC4 and survivin RNA. (English)

1 reference

5 February 2018

1 reference

1 reference

Jiang Chen

1

1 reference

5 February 2018

Xiao-Zhong Guo

2

1 reference

5 February 2018

Hong-Yu Li

3

1 reference

5 February 2018

Xu Liu

4

1 reference

5 February 2018

Li-Nan Ren

5

1 reference

5 February 2018

Di Wang

6

1 reference

5 February 2018

Jia-Jun Zhao

7

1 reference

5 February 2018

language of work or name

English

0 references

publication date

6 August 2013

1 reference

5 February 2018

published in

Vaccine

1 reference

5 February 2018

volume

31

1 reference

5 February 2018

issue

41

1 reference

5 February 2018

page(s)

4585-4590

1 reference

5 February 2018

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

1 reference

Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Cellular vaccine approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Dendritic cell-based cancer immunotherapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Tumor vaccine therapy against recrudescent tumor using dendritic cells simultaneously transfected with tumor RNA and granulocyte macrophage colony-stimulating factor RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Prognostic value of mucin 4 expression in colorectal adenocarcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Aberrant upregulation of MUC4 mucin expression in cutaneous condyloma acuminatum and squamous cell carcinoma suggests a potential role in the diagnosis and therapy of skin diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Significance of mucin expression in pancreatobiliary neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Novel INTeraction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Muc4/MUC4 functions and regulation in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Survivin and pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Induction of cytotoxic T lymphocytes primed with tumor RNA-loaded dendritic cells in esophageal squamous cell carcinoma: preliminary step for DC vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

MUC4 gene polymorphism and expression in women with implantation failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

Current diagnosis and treatment of pancreatic cancer in China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.055

10.1016/J.VACCINE.2013.07.055

7 January 2021

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018